JP2020533380A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533380A5
JP2020533380A5 JP2020515138A JP2020515138A JP2020533380A5 JP 2020533380 A5 JP2020533380 A5 JP 2020533380A5 JP 2020515138 A JP2020515138 A JP 2020515138A JP 2020515138 A JP2020515138 A JP 2020515138A JP 2020533380 A5 JP2020533380 A5 JP 2020533380A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
combination drug
seq
drug according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/056969 external-priority patent/WO2019053613A2/en
Publication of JP2020533380A publication Critical patent/JP2020533380A/ja
Publication of JP2020533380A5 publication Critical patent/JP2020533380A5/ja
Priority to JP2022173704A priority Critical patent/JP2023015171A/ja
Pending legal-status Critical Current

Links

JP2020515138A 2017-09-14 2018-09-12 癌の組合せ治療 Pending JP2020533380A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022173704A JP2023015171A (ja) 2017-09-14 2022-10-28 癌の組合せ治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558608P 2017-09-14 2017-09-14
US62/558,608 2017-09-14
PCT/IB2018/056969 WO2019053613A2 (en) 2017-09-14 2018-09-12 POLY THERAPY FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022173704A Division JP2023015171A (ja) 2017-09-14 2022-10-28 癌の組合せ治療

Publications (2)

Publication Number Publication Date
JP2020533380A JP2020533380A (ja) 2020-11-19
JP2020533380A5 true JP2020533380A5 (https=) 2021-10-21

Family

ID=63713946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515138A Pending JP2020533380A (ja) 2017-09-14 2018-09-12 癌の組合せ治療
JP2022173704A Pending JP2023015171A (ja) 2017-09-14 2022-10-28 癌の組合せ治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022173704A Pending JP2023015171A (ja) 2017-09-14 2022-10-28 癌の組合せ治療

Country Status (7)

Country Link
US (2) US20200255526A1 (https=)
EP (1) EP3692066A2 (https=)
JP (2) JP2020533380A (https=)
CN (1) CN111094353A (https=)
BR (1) BR112020005028A2 (https=)
CA (1) CA3075717A1 (https=)
WO (1) WO2019053613A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MX2022011027A (es) * 2020-03-06 2022-12-13 Aleta Biotherapeutics Inc Composiciones y metodos para el tratamiento del cancer.
EP4363999A1 (en) * 2021-06-28 2024-05-08 Voredos N-hamming distance search and n-hamming distance search index
CN119212735A (zh) * 2023-04-27 2024-12-27 石药集团巨石生物制药有限公司 一种抗体药物偶联物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン,エルエルシー 抗体製剤
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
US20130101599A1 (en) * 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Cd269(bcma)に対する抗体
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
WO2015158671A1 (en) 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
JP6285274B2 (ja) 2014-04-28 2018-02-28 株式会社ブリヂストン バイアスタイヤ及びその製造方法
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對icos之抗體
PL3988117T3 (pl) * 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
EP3147954A1 (en) 2015-09-22 2017-03-29 Nokia Technologies Oy Photodetector with conductive channel made from two dimensional material and its manufacturing method
EP4015537A1 (en) * 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4295918A3 (en) * 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma

Similar Documents

Publication Publication Date Title
JP2020533380A5 (https=)
JP2020500538A5 (https=)
JP2019110906A5 (https=)
JP2018505177A5 (https=)
JP2017528476A5 (https=)
JP2019528083A5 (https=)
JP2018536624A5 (https=)
JP2021529557A5 (https=)
JP2020079252A5 (https=)
RU2018147413A (ru) PD-L1 специфические антитела
JP2018035138A5 (https=)
JP2018507220A5 (https=)
RU2018123717A (ru) Комбинированные лечения, их применения и способы
JP2017514795A5 (https=)
JP2011046732A5 (https=)
FI3740504T3 (fi) CD70-yhdistelmähoito
JP2014520088A5 (https=)
JP2019522961A5 (https=)
JP2017535257A5 (https=)
JP2020516240A5 (https=)
JP2017534577A5 (https=)
RU2020111366A (ru) Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
JP2016505546A5 (https=)
JP2013515472A5 (https=)
JP2019531764A5 (https=)